Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. - Wikidata - awgldk - TriplyDB

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.

http://www.wikidata.org/entity/Q34619064

about

Natalizumab for relapsing remitting multiple sclerosis Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?The changing landscape of progressive multifocal leukoencephalopathy.Best practice in the use of natalizumab in multiple sclerosis.Infection risk in patients on multiple sclerosis therapeutics.Effects of natalizumab treatment on Foxp3+ T regulatory cells.Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project Severe haematological complications during treatment with natalizumab.Progressive multifocal leukoencephalopathy in HIV-1 infection.Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report.Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor: structure optimization and pharmacokinetics Escalating immunotherapy of multiple sclerosis.Natalizumab in the treatment of multiple sclerosis Therapeutic strategies in childhood multiple sclerosis Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.Treating multiple sclerosis with monoclonal antibodies.JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy.Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.Natalizumab for the treatment of relapsing multiple sclerosis.Randomized controlled trial design in rheumatoid arthritis: the past decade.Treating multiple sclerosis with monoclonal antibodies: a 2010 update.Progressive multifocal leukoencephalopathy: what's new?Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges.Innovative monoclonal antibody therapies in multiple sclerosis.Managing MS in a changing treatment landscape.Progressive multifocal leukoencephalopathy and natalizumab.Treating multiple sclerosis with natalizumab.Multiple sclerosis (MS) for the urologist: What should urologists know about MS?Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update.Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.Seroprevalence rates of BKV, JCV, and MCPyV polyomaviruses in the general Czech Republic population.Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells.Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis.Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy.

P2860

Q24235861-3F3C93EE-AB1C-42C9-9E56-148838173DAD Q26823444-9820732E-1120-4231-BC24-0713C756F2D2 Q26852060-D221FE82-30BB-4EA3-9F4C-59D0B1DF3BE4 Q30403035-CC9EDBE6-9C4A-4C8C-9DC8-13DFA7AAE3C1 Q30597618-0EDB9445-70FB-4F16-ACDD-6B22A9A4C07D Q30908652-8F96AEBA-197E-4C22-9802-27309D707668 Q33373995-6F670A17-EE8F-41A6-AB08-A321B194C514 Q33383576-D9193048-2030-4464-A9DA-B08C9B51A98B Q33400350-E29FA430-4A76-43E9-9049-D9F955086A53 Q33506561-97E030B2-AA5E-4FB4-8A93-85848EB78291 Q33581135-F440F1DE-86BD-4681-81F9-1889AF8A68E9 Q33714913-4D5F4F1D-C2EA-4AC4-8222-0DF8FA9FA3EE Q34409100-196DADFF-A891-4C9A-9F64-843C3C6948BD Q34409340-53A327D8-AFBE-48E5-BF96-61388AF196C1 Q34409508-144E7FC9-BA5A-43D4-9F0C-D1C8B846D25E Q35589934-CDA510DE-507A-409F-9165-2DC03BE4A0DD Q35609239-9CF70A6D-03A2-408E-9607-B69E2034B836 Q36508862-2C852D95-0ABB-4C79-8F34-A43393C5B949 Q36748702-A724736D-BF5C-4FF8-9A7F-DD37134A959D Q37111904-29CE8E17-AEF0-4826-9A5B-A0A9CC576B92 Q37157144-CDE266D4-361F-4EE7-85D1-C1AC4ACC5D5C Q37180600-E1350343-5036-45FA-A9B2-FD77CBEB7C7A Q37290643-84347F56-A1E6-4FFD-819A-DC6D6564C044 Q37397646-FA2F1CAC-B6B8-46A6-940B-794657A97F1E Q37737305-D749D360-74B1-45F2-9521-AC61732B753E Q37755922-DE604480-D62F-46A6-A337-148401700D96 Q37778944-6B9FA8EE-26BB-47B9-BE87-B4CBCAD29AB7 Q37814815-55DC6127-5B1A-4120-B7C7-743091BBC346 Q37823315-6B906207-CA42-4E94-B103-9464CA42B421 Q37857752-4CE83120-7AC6-4E14-BC5D-D07C0003BABD Q37885823-0B1D1ED3-C029-47E6-9322-EC9744E7E5D3 Q37957123-81A417D4-AD89-41F4-9663-97EE73F07FF0 Q38331840-C9D43E0B-2C9A-4AB3-B30E-F224D104C672 Q38616689-E5EB4652-F51E-44A8-9F95-086D1FD49E03 Q38793624-B78F5F8A-D359-4151-8817-FEE7450CF148 Q39064776-706EED8B-C482-4420-96FD-30DE7615B053 Q39587782-1292B5C5-72AF-4878-934D-209D1DF3F2A9 Q41173582-462FF45E-4FE8-4A08-9CFA-2BD134C4C075 Q41386664-7466CC92-9230-4299-A169-50187F0E0C7A Q44272607-A5846AAE-C745-41D4-B022-22DB4D09866E

P2860

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.

http://www.wikidata.org/entity/Q34619064

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Natalizumab treatment for mult ...... ient selection and monitoring.

@ast

Natalizumab treatment for mult ...... ient selection and monitoring.

@en

Natalizumab treatment for mult ...... ient selection and monitoring.

@nl

type

label

Natalizumab treatment for mult ...... ient selection and monitoring.

@ast

Natalizumab treatment for mult ...... ient selection and monitoring.

@en

Natalizumab treatment for mult ...... ient selection and monitoring.

@nl

prefLabel

Natalizumab treatment for mult ...... ient selection and monitoring.

@ast

Natalizumab treatment for mult ...... ient selection and monitoring.

@en

Natalizumab treatment for mult ...... ient selection and monitoring.

@nl

P1433

Q34619064-97A37111-FA76-4B23-877B-07BA2D703B67

P1476

Q34619064-06AB76F1-39EA-4CBD-95F7-98156D9311EE

P2093

Q34619064-1991726B-2DF4-4F95-9921-FD6C0992626E

Q34619064-23E972F1-8A75-42B5-A09A-1FE8AF2F8871

Q34619064-2D7DC67C-669B-4EFE-8C43-694CD12F982C

Q34619064-3F20C66E-9C61-4B6C-B5C8-FE1738E82638

Q34619064-465A80B6-0E6D-4C92-BF4A-5567720460C3

Q34619064-46CDD6F4-32AC-4966-97DC-41EDC7035427

Q34619064-616227BC-20BA-41A9-8B4C-6347EDF9091F

Q34619064-661FF938-3C5D-434C-A045-8B8EC08ED90F

Q34619064-6717DDC2-DCF6-421B-B6A0-7D6D62A2F4D4

Q34619064-6EFC75E1-C40D-4A18-9385-230298234543

P304

Q34619064-3E38DA72-16EB-4F62-9B76-62288AA7E2D2

P31

Q34619064-5F05DA13-3463-4FF9-B576-C70A6FE5C456

P356

Q34619064-CDC25900-FF13-4A39-B7F4-7D22D99AE931

P433

Q34619064-37E342C9-A973-4474-A159-C8164314E41F

P478

Q34619064-18A29032-5904-4AEF-8BB7-F99CBC75026D

P50

Q34619064-0833A6AD-A14E-46E6-B3CA-8AC511BE5E03

Q34619064-836DC274-B77D-49AA-A09B-2F8AE5F8982C

Q34619064-BE9D5682-2881-4B8A-8F10-C2E180FC436C

P577

Q34619064-1AFD9542-5A0A-443D-B166-37C531F6C28A

P698

Q34619064-8596512D-5ECB-472D-9274-715E2CC149CF

P921

Q34619064-0EB27CD2-39EC-4B4A-8F65-5510942FD970

Q34619064-4CDAC423-EEAC-4BFF-B3E8-61888D284893

P356

S1474-4422(07)70078-9

P1433

Lancet Neurology

P1476

Natalizumab treatment for mult ...... ient selection and monitoring.

@en

P2093

Chris H Polman

http://www.w3.org/2001/XMLSchema#string

David B Clifford

http://www.w3.org/2001/XMLSchema#string

David Bates

http://www.w3.org/2001/XMLSchema#string

David Miller

http://www.w3.org/2001/XMLSchema#string

Ernst Wilhelm Radue

http://www.w3.org/2001/XMLSchema#string

Eugene O Major

http://www.w3.org/2001/XMLSchema#string

Eva Havrdova

http://www.w3.org/2001/XMLSchema#string

John King

http://www.w3.org/2001/XMLSchema#string

Mads Ravnborg

http://www.w3.org/2001/XMLSchema#string

Paul W O'Connor

http://www.w3.org/2001/XMLSchema#string

P304

431-441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1474-4422(07)70078-9

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Howard L. Weiner

Hans-Peter Hartung

P577

2007-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17434098

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis